BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       

Keratoacanthoma

Keratoacanthoma is a relatively common, benign, epithelial tumor that was previously considered to be a variant of squamous cell carcinoma . The etiology is unknown. No human papillomavirus-DNA sequences were detected in lesions by polymerase chain reaction. It is a disease of the elderly with an annual incidence rate of 104 per 100,000. It is not associated with internal malignancy. There may be a seasonal presentation of keratoacanthoma that suggests that ultraviolet radiation has an acute effect on the development of KA. KAs may develop in sites of previous trauma. Most cases are the “crateriform” type, which grow rapidly then undergo spontaneous regression. Less than 2% belong to the rare destructive variants with no regression and persistent invasive growth. These are referred to as keratoacanthoma marginatum centrifugum and mutilating keratoacanthomas and can lead to severe defects. KA begins as a smooth, dome-shaped, red papule that resembles molluscum contagiosum. In a few weeks the tumor may rapidly expand to 1 or 2cm and develop a central keratin-filled crater that is frequently filled with crust. The growth retains its smooth surface, unlike a squamous cell carcinoma. Untreated, growth stops in approximately 6 weeks, and the tumor remains unchanged for an indefinite period. In the majority of cases it then regresses slowly over 2 to 12 months and frequently heals with scarring. The limbs, particularly the sun-exposed hands and arms, are the most common site; the trunk is the second most common site, but KA may occur on any skin surface, including the anal area. On occasion, multiple KAs appear, or a single lesion extends over several centimeters. These variants resist treatment and are unlikely to undergo spontaneous emission.According to a review of literature by Robert A. Schwartz, KA was once considered a benign neoplasm that resembled a highly malignant one , but it is now viewed in an opposite light as a cancer that resembles a benign neoplasm . KA is an abortive malignancy that rarely progresses into an invasive SCC. The KA may serve as a marker for the important autosomal dominant familial cancer syndrome, the Muir-Torre syndrome, as a result of a defective DNA mismatch repair gene.[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=14871228&query_hl=2&itool=pubmed_docsum] (From the Wikpedia article Keratoacanthoma.)

Download PDF PDF Version

Image Results

Loading...

Recent Publications on Keratoacanthoma:

Pubmed Logo
Immunohistochemical staining for the differentiation of subungual keratoacanthoma from subungual squamous cell carcinoma.
Background. Subungual keratotic tumours are rare. The clinical and...
12th July, 2008
Department of Dermatology and Histopathology, Bristol Royal Infirmary, Clin Exp Dermatol. 2008 Jun 25;.
DOI Direct Link
Site and tumor type predicts DNA mismatch repair status in cutaneous sebaceous neoplasia.
Cutaneous sebaceous neoplasia is known to exhibit a high degree of DNA...
4th July, 2008
Department of Pathology, Section ofDermatopathology, School of Pathology, Am J Surg Pathol. 2008 Jun;32(6):936-42.
Grzybowski's keratoacanthoma - the man behind the eponym.
The first textbook of dermatology in Poland was written in the 20th...
2nd July, 2008
Department of History of Medicine, Poznan University School of Medical Med Sci Monit. 2008 Jul;14(7):MH1-3.
Squamous cell carcinoma developing in a naevus sebaceous of Jadassohn.
Squamous cell carcinoma developing within a naevus sebaceus of Jadassohn...
27th June, 2008
Royal Liverpool and Broadgreen University Hospitals, Thomas Drive, Am J Dermatopathol. 2008 Jun;30(3):269-70.
DOI Direct Link
CD30+ cell population in common keratoacanthomas: a study of 21 cases.
Many examples of epidermal pseudocarcinomatous proliferations associated...
3rd June, 2008
Service of Anatomic Pathology, Hospital El Bierzo, Service of Cellular Rom J Morphol Embryol. 2008;49(2):159-62.

View more research publications.

Keratoacanthoma Patents:

USPTO Logo
US Patent No.Title
7078425 Preparation of phosphatase inhibitors
7169778 Pteridinones as kinase inhibitors
7183307 Pyrazole-derived kinase inhibitors and uses thereof
7192586 Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate specific membrane antigen
7208489 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones

View more patents.

BioPortfolio Ltd. offers e-mail and postal lists for Keratoacanthoma scientists - we have details of around 155 individuals working on Keratoacanthoma .


This page has been viewed 131 times
Recent Search Terms used to find this page: keratoacanthoma | keratoacanthoma | keratoacanthoma | keratoacanthoma | keratoacanthoma | keratoacanthoma | keratoacanthoma | keratoacanthoma and the incidence of scc | keratoacanthoma | .
Browse BioPortfolio's InDepth service - alphabetically: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z or by Most Publications, recently searched for, or most viewed.

Search for Keratoacanthoma across BioPortfolio, or bestselling Keratoacanthoma books or recently published Keratoacanthoma books .
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH.
 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

BioPortfolio logo

Valid XHTML 1.0 Transitional